Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases

British Journal of Radiology - Tập 93 Số 1108 - 2020
C.L. Deantoni1, A. Fodor1, C. Cozzarini1, C. Fiorino2, Chiara Brombin3,4, Marco Scarsini3,4, R. Calandrino2, N. Di Muzio1,4
1Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
2Department of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, Italy
3University Centre of Statistics in the Biomedical Sciences (CUSSB), Vita-Salute San Raffaele University, Milan, Italy
4Vita-Salute San Raffaele University, Milan, Italy

Tóm tắt

Objective: To evaluate toxicity and clinical outcome in synchronous bone only oligometastatic (≤2 lesions) prostate cancer patients, simultaneously irradiated to prostate/prostatic bed, lymph nodes and bone metastases. Methods: From 2/2009 to 6/2015, 39 bone only prostate cancer patients underwent radiotherapy (RT) at “radical” doses to bone metastases (median 2 Gy equivalent dose, EQD2>40Gy, α/β = 1,5), nodes, and prostate/prostatic bed, within the same RT course, in association with androgen deprivation therapy (ADT). Biochemical relapse-free survival, clinical relapse-free survival, freedom from distant metastases and overall survival were evaluated. Results: After a median follow-up of 46.5 (1.2–103.6) months, 5 patients died from disease progression, 10 experienced biochemical relapse, 19, still in ADT, presented undetectable prostate-specific antigen (PSA) at the last follow-up. Five patients who discontinued ADT after a median of 34 months (5.8–41) are free from biochemical relapse. The 4 year Kaplan–Meier estimates of biochemical relapse-free survival, clinical relapse-free survival, freedom from distant metastases and overall survival were 53.3%, 65.7%, 73.4% and 82.4% respectively. No Grade > 2 acute events and only two severe late urinary events were recorded, not due to the concomitant treatment of primary and metastatic disease. Conclusion: Our results suggest that “radical” and synchronous irradiation of primitive tumor and metastatic disease may be a valid approach in synchronous bone only prostate cancer patients, showing mild toxicity profile and promising survival results. Advances in knowledge: To the best of our knowledge, this is the first analysis of clinical outcome in synchronous bone-only metastasis (neither nodal nor visceral) patients at diagnosis, treated with radical RT to all disease, associated to ADT.

Từ khóa


Tài liệu tham khảo

Bolla, 2010, External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 11, 1066, 10.1016/S1470-2045(10)70223-0

Bolla, 2016, Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991, J Clin Oncol, 34, 1748, 10.1200/JCO.2015.64.8055

Pilepich, 2005, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31, Int J Radiat Oncol Biol Phys, 61, 1285, 10.1016/j.ijrobp.2004.08.047

Mottet, 2017, EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer

Joon, 1997, Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation, Int J Radiat Oncol Biol Phys, 38, 1071, 10.1016/S0360-3016(97)00303-9

Falchook, 2016, Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate risk prostate cancer, Cancer, 122, 2341, 10.1002/cncr.30049

Burdett, 2019, Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis, Eur Urol, 76, 115, 10.1016/j.eururo.2019.02.003

Parker, 2018, Radiotherapy to the primary tumor for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial, Lancet, 10.1016/S0140-6736(18)32486-3

Boeve, 2018, Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial, Eur Urol, 14, 135

Pollack, 2018, Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: the NRG Oncology/RTOG 0534 SPPORT trial, ASTRO

Roach, 2006, Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial, Int J Radiat Oncol Biol Phys, 66, 647, 10.1016/j.ijrobp.2006.05.074

Furuya, 1999, Pattern of progression and survival in hormonally treated metastatic prostate cancer, Int J Urol, 6, 240, 10.1046/j.1442-2042.1999.00060.x

Jereczek-Fossa, 2012, Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer, Int J Radiat Oncol Biol Phys, 82, 889, 10.1016/j.ijrobp.2010.11.031

Verhagen, 2010, Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? a systematic review, Eur Urol, 58, 261, 10.1016/j.eururo.2010.05.027

Halabi, 2014, The site of visceral metastases to predict overall survival in castration-resistant prostate cancer patients: a meta-analysis of five phase III trials, J Clin Oncol, 32, 10.1200/JCO.2013.52.3696

Ost, 2014, Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer, Prostate, 74, 297, 10.1002/pros.22750

Morgan, 2007, Radiation dose and late failures in prostate cancer, Int J Radiat Oncol Biol Phys, 67, 1074, 10.1016/j.ijrobp.2006.10.023

Picchio, 2012, [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy, Eur J Nucl Med Mol Imaging, 39, 13, 10.1007/s00259-011-1920-z

Fiorino, 2008, Physics aspects of prostate tomotherapy: planning optimization and image-guidance issues, Acta Oncol, 47, 1309, 10.1080/02841860802266755

Cozzarini, 2004, Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients, Int J Radiat Oncol Biol Phys, 59, 674, 10.1016/j.ijrobp.2003.12.001

Fodor, 2017, Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer, BJU Int, 119, 406, 10.1111/bju.13510

Tabata, 2012, Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer, Pulm Med, 2012, 1, 10.1155/2012/541656

Singh, 2004, Is there a favorable subset of patients with prostate cancer who develop oligometastases?, Int J Radiat Oncol Biol Phys, 58, 3, 10.1016/S0360-3016(03)01442-1

Cozzarini, 2014, Higher than expected Severe (grade 3–4) late urinary toxicity after post-prostatectomy hypofractionated radiotherapy: a single institution analysis of 1176 patients, Eur Urol, 66, 1024, 10.1016/j.eururo.2014.06.012

Tomioka, 2014, Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer, BMC Urol, 14, 10.1186/1471-2490-14-33

Miyamoto, 2012, Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy, Prostate Cancer Prostatic Dis, 15, 75, 10.1038/pcan.2011.47

Sasaki, 2011, Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis, Prostate Cancer Prostatic Dis, 14, 248, 10.1038/pcan.2011.14

Muacevic, 2013, Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer, Urol Oncol, 31, 455, 10.1016/j.urolonc.2011.02.023

Ahmed, 2013, Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer, Front Oncol, 2, 10.3389/fonc.2012.00215

Decaestecker, 2014, Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence, Radiat Oncol, 9, 135, 10.1186/1748-717X-9-135

Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, JCO, 10.1200/JCO.2017.75.3657

Fizazi, 2019, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, Lancet Oncol, 20, 686, 10.1016/S1470-2045(19)30082-8

Thông tin
Thông tin xuất bản

British Journal of Radiology

Tập 93 Số 1108

Thông tin tác giả